Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry

TY - JOUR

T1 - Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry

AU - Swart, L.

AU - Johnston, W Thomas

AU - Smith, Alexandra

AU - Fenaux, Pierre

AU - Symeonidis, Argiris

AU - Cermak, Jaroslav

AU - Hellström-Lindberg, Eva

AU - Sanz, Guillermo

AU - Stauder, Reinhard

AU - Malcovati, Luca

AU - Germing, Ulrich

AU - Huls, Gerwin

AU - Holm, Mette

AU - Mittelman, Moshe

AU - Madry, K.

AU - Tatic, A.

AU - Almeida, Antonio

AU - Savic, Aleksandar

AU - Park, Sophie

AU - Witte, Theo

N1 - Conference code: 57

PY - 2015/12/3

Y1 - 2015/12/3

N2 - Background The outcome of lower-risk MDS patients with red blood cell transfusions (RBCT) dependency is inferior to that of RBCT independent patients, but whether the intensity of RBCT is important for prognosis is unknown. The EUMDS Registry is a non-interventional, observational longitudinal study enrolling patients with lower-risk MDS from 142 sites in 17 countries as described elsewhere (1). The EUMDS registry has accrued 1,902 patients as of July 21, 2015. We hypothesized that RBCT intensity is an independent prognostic factor for survival. Methods We first assessed the impact of RBCT intensity in the first year post-diagnosis (1yrPD) on progression-free survival among the 1034 patients who survived at least 1yrPD and had potential for a further year of follow-up. Secondly, we developed a longitudinal model of platelet counts throughout follow-up for 1660 patients in the registry with potential for at least one year follow-up. Results Among the 1034 patients, 323 patients had died: 67 after progression to higher-risk MDS/AML and 256 without progression. A further 41 surviving patients had progressed to AML. The overall 5-year survival was 52%. In a proportional hazards regression model (Table), the risk of death or progression increased in a non-linear fashion with age at diagnosis (p

AB - Background The outcome of lower-risk MDS patients with red blood cell transfusions (RBCT) dependency is inferior to that of RBCT independent patients, but whether the intensity of RBCT is important for prognosis is unknown. The EUMDS Registry is a non-interventional, observational longitudinal study enrolling patients with lower-risk MDS from 142 sites in 17 countries as described elsewhere (1). The EUMDS registry has accrued 1,902 patients as of July 21, 2015. We hypothesized that RBCT intensity is an independent prognostic factor for survival. Methods We first assessed the impact of RBCT intensity in the first year post-diagnosis (1yrPD) on progression-free survival among the 1034 patients who survived at least 1yrPD and had potential for a further year of follow-up. Secondly, we developed a longitudinal model of platelet counts throughout follow-up for 1660 patients in the registry with potential for at least one year follow-up. Results Among the 1034 patients, 323 patients had died: 67 after progression to higher-risk MDS/AML and 256 without progression. A further 41 surviving patients had progressed to AML. The overall 5-year survival was 52%. In a proportional hazards regression model (Table), the risk of death or progression increased in a non-linear fashion with age at diagnosis (p

U2 - 10.1182/blood.V126.23.1677.1677

DO - 10.1182/blood.V126.23.1677.1677

M3 - Meeting abstract

SN - 0006-4971

VL - 126

SP - 1677

JO - Blood

JF - Blood

IS - 23

M1 - 637

T2 - 57th ASH Annual Meeting & Exposition

Y2 - 5 December 2015 through 8 December 2015

ER -